Literature DB >> 17083032

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

Hassane Izzedine1, Jean-Sebastien Hulot, Eric Villard, Catherine Goyenvalle, Stephanie Dominguez, Jade Ghosn, Marc Antoine Valantin, Philippe Lechat, And Gilbert Deray.   

Abstract

BACKGROUND: Tenofovir disoproxil fumarate (TDF) may induce renal proximal tubulopathy (rPT). There are no data on pharmacogenomic predictors of rPT in the genes encoding the multidrug-resistance protein (MRP) 2 and MRP4 transporters.
METHODS: Mutational screening of the genes for MRP2 (ABCC2) and MRP4 (ABCC4) was performed using genomic DNA from 13 human immunodeficiency virus type 1 (HIV-1)-infected patients (group 1) presenting with TDF-induced rPT. Concomitantly, 17 unrelated HIV-1-infected patients who had received TDF therapy and who did not have rPT (group 2) were included in a case-control analysis, to assess the influence of single-nucleotide polymorphisms (SNPs) identified in ABCC2 and ABCC4.
RESULTS: Six SNPs were identified in ABCC2. A significant allelic association between the 1249 G-->A SNP and TDF-induced rPT was observed (odds ratio, 6.11 [95% confidence interval, 1.19-31.15]; P<.02). ABCC2 haplotypes were significantly associated with the onset of TDF-induced rPT--CATC appeared to be a predisposing haplotype, as it was found in 40.9% of the group 1 case patients and in 13.7% of the group 2 control subjects (P<.01), whereas CGAC appeared to be a protective haplotype, as it was not observed in the group 1 case patients but was present in 20.2% of the group 2 control subjects (P<.01). No association was observed between ABCC4 polymorphism and TDF-induced rPT in the present study.
CONCLUSION: ABCC2 haplotypes are associated with rPT induced by TDF in HIV-1-infected patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083032     DOI: 10.1086/508546

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

1.  Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Authors:  Victor Asensi; Julio Collazos; Eulalia Valle-Garay
Journal:  World J Virol       Date:  2015-08-12

Review 2.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

Review 3.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

4.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Authors:  Pedro Rodríguez Quesada; Laura López Esteban; Jimena Ramón García; Rocío Vázquez Sánchez; Teresa Molina García; Gabriel Gaspar Alonso-Vega; Javier Sánchez-Rubio Ferrández
Journal:  Int J Clin Pharm       Date:  2015-05-26

Review 5.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 6.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

7.  A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.

Authors:  Amber Dahlin; Matthias Wittwer; Melanie de la Cruz; Jonathan M Woo; Rujuta Bam; Valeska Scharen-Guivel; John Flaherty; Adrian S Ray; Tomas Cihlar; Samir K Gupta; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

Review 8.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

9.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 10.  The nephrotoxic effects of HAART.

Authors:  Hassane Izzedine; Marianne Harris; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.